News and Scientific Presentations

Empirium

Hemab’s scientific legacy in action. Explore our complete collection of presentations and publications documenting our journey to advance understanding of overlooked bleeding disorders.

Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study

ASH 2025: Sutacimig - A Novel Bispecific Antibody for Prophylactic Treatment of Glanzmann Thrombasthenia: Analysis of a Phase 2 Study

Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders

BIC 2025: VELORA Pioneer - Preliminary Safety and PK/PD Data of a First-in-Human Study of HMB-002 in Type 1 Von Willebrand Disease

Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer

ISTH 2025: Sutacimig - A Novel Prophylactic Treatment for Glanzmann Thrombasthenia: Interim Analysis of a Phase 1/2 Study

ISTH 2025: Favorable nonclinical safety profile of HMB-002 for prophylactic treatment of Von Willebrand disease

ISTH 2025: VELORA Pioneer - Preliminary safety and PK/PD data of a first-in-human study of HMB-002 in Type 1 Von Willebrand disease

ISTH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress

WFH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF) The Potential of HMB-002 as Prophylactic Treatment of von Willebrand Disease (VWD)

WFH 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress

EAHAD 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

EAHAD 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study

HMB-001 A bispecific antibody accumulating and targeting endogenous fviia to activated platelets enhances thrombin generation and fibrin formation for subcutaneous prophylaxis in Glanzmann Thrombasthenia

Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study

Novo Holdings Creates New, Rare Bleeding Disorder Company, Hemab

ASH 2025: Sutacimig - A Novel Bispecific Antibody for Prophylactic Treatment of Glanzmann Thrombasthenia: Analysis of a Phase 2 Study

BIC 2025: VELORA Pioneer - Preliminary Safety and PK/PD Data of a First-in-Human Study of HMB-002 in Type 1 Von Willebrand Disease

ISTH 2025: Sutacimig - A Novel Prophylactic Treatment for Glanzmann Thrombasthenia: Interim Analysis of a Phase 1/2 Study

ISTH 2025: Favorable nonclinical safety profile of HMB-002 for prophylactic treatment of Von Willebrand disease

ISTH 2025: VELORA Pioneer - Preliminary safety and PK/PD data of a first-in-human study of HMB-002 in Type 1 Von Willebrand disease

ISTH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

WFH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF) The Potential of HMB-002 as Prophylactic Treatment of von Willebrand Disease (VWD)

WFH 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

EAHAD 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

EAHAD 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

HMB-001 A bispecific antibody accumulating and targeting endogenous fviia to activated platelets enhances thrombin generation and fibrin formation for subcutaneous prophylaxis in Glanzmann Thrombasthenia

EAHAD 2024: Interim Results of the First-in-Human Investigation of HMB-001 for Prophylactic Management of Glanzmann Thrombasthenia

Nordic Platelet Symposium: HMB-001 | A Novel Bispecific Antibody Accumulating and Targeting Endogenous FVIIa to Activated Platelets for Subcutaneous Prophylaxis in Multiple Bleeding Disorders Including Glanzmann Thrombasthenia

BSHT 2023: HMB-001 - a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets supports enhanced haemostatic responses in models of Glanzmann’s thrombasthenia

HMB-001 A Novel Bispecific Antibody Accumulating and Targeting Endogenous FVIIa to Activated Platelets for Subcutaneous Prophylaxis in Multiple Bleeding Disorders Including Glanzmann Thrombasthenia

EAHAD 2022: HMB-001 A novel bispecific antibody with potential for subcutaneous prophylactic treatment of multiple bleeding disorders initial focus on Glanzmann Thrombasthenia (GT)

PB0719 The Novel Bispecific Antibody HMB-001 Enhances the Haemostatic Response in Models of Glanzmann Thrombasthenia by Targeting FVIIa to Activated Platelets

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders